• JAK1 inhibitor shows promising long-term efficacy in PN

    Povorcitinib led to a sustained reduction of pruritus and skin lesions in prurigo nodularis in a randomised-controlled phase 2 study.

  • HS: Bimekizumab shows sustained 2-year efficacy

    Continuing bimekizumab for 2 years led to maintenance of various HiSCR and International Hidradenitis Suppurativa Severity Score System (IHS4) scores.

  • Second-generation selective PDE-4 inhibitor shows promise in AD

    Orismilast demonstrated higher rates of Investigator Global Assessment of 0/1 at week 16 compared with placebo in the phase 2b ADESOS trial.

  • Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

    A comparison of topical delgocitinib with systemic alitretinoin for treating patients with chronic hand eczema (CHE) favoured the pan-JAK inhibitor.

  • PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis

    A comprehensive analysis from the German Psoriasis Registry (PsoBest) highlights the evolution of systemic drug use for psoriasis over the past 15 years.

  • Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia

    Delgocitinib was associated with a reduction in interferon gamma (IFN-γ), chemokine ligand (CXCL)9, and CXCL10 in the treatment of FFA.

  • Atopic dermatitis early in life imposes a lifelong psychosocial burden

    A study including data from over 30,000 participants revealed that early onset of atopic dermatitis (AD) leads to a psychosocial burden throughout adult life.

  • Prurigo nodularis: long-term treatment reduces relapse events

    Withdrawing nemolizumab led to an 8-fold increase in the likelihood of a prurigo nodularis (PN) relapse compared with uninterrupted therapy.

  • Autism: diagnosis through the eyes?

    A combination of eye-tracking tests could help to speed up the diagnostic process and make it more efficient, according to the authors.

  • Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis

    A single dose of 750 mg imsidolimab yielded a GPPPGA score of clear or almost clear in over half of the participants with GPP after 4 weeks.

  • Targeting IL-17A: a promising treatment perspective in hidradenitis suppurativa

    Izokibep treatment for hidradenitis suppurativa (HS) met its primary endpoint of HS Clinical Response (HiSCR)75 in an ongoing phase 3 trial.

  • New targets identified for chronic wound healing

    A study using full-thickness human skin punches identified critical molecular targets that could transform the treatment of both acute and chronic wounds.

  • Bipolar disorder: is magnetic seizure therapy a treatment option?

    In the randomised study, participants were treated either with magnetic seizure therapy (MST) or with Electroconvulsive Therapy (ECT). What were the results?

  • Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

    Histologic risk status at diagnosis and the time needed to achieve complete remission (CR) may influence the prospect of a relapse after HHI treatment.

  • Semaglutide: also beneficial for patients with HS?

    In patients with hidradenitis suppurativa and obesity, therapy led to significant weight loss, reduced flares and improved quality-of-life.

  • Anti-KIT antibody: the next frontier in CSU treatment?

    A novel anti-KIT antibody demonstrated high rates of well-controlled and fully controlled disease after 1 year of treating chronic spontaneous urticaria.

  • IL-13 inhibitor shows safety and efficacy in AD over 3 years

    The EASI90 response in the extension study ADjoin even increased over time with around 80% of patients achieving this high clearance rate at 152 weeks.

  • Atopic hand eczema: similar treatment success for dupilumab and delgocitinib

    Indirect matching-adjusted comparison assessing delgocitinib cream and subcutaneous dupilumab did not detect significant differences in treatment.

  • Soft drinks increase liver cancer and liver-related mortality

    Sugary drinks cause weight gain and heart damage. Regarding liver damage, US researchers argue it may depend on the sweeteners.

  • New research confirms link between perceived stress and psoriasis flare-ups

    The study shows how stress triggers relapses. It was presented at the EADV Congress 2024 and scientifically confirms the correlation for the first time in vivo.

  • 1 |
  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |